Establishing the Role of Targeted Therapies in Cancer Care | PTCE Pharmacy Connect

Educational Objectives
·             Describe the role of immune checkpoint inhibitor (ICI)-targeted therapy combinations across malignancies
·             Recall knowledge of ICI-targeted therapy combinations to treatment selection in patients with cancer
 
Faculty:
Jacob K. Kettle, PharmD, BCOP
Pharmacy Manager
Ellis Fischel Cancer Center
Department of Pharmacy
University of Missouri Health Care
Columbia, Missouri

Faculty, has the following financial relationships with commercial interests to disclose:
Jacob Kettle, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Speakers Bureau: Genentech, Merck, Amgen, Lilly, DSI
Consultant: Pfizer, Lilly

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-21-437-H01-P. The activity is available for CE credit through December 17, 2022.
This activity is supported by educational grants from Eisai Inc and Exelixis, Inc.
Learn more about your ad choices. Visit megaphone.fm/adchoices